Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
Condition(s):Prader-Willi Syndrome; ObesityLast Updated:January 26, 2017Terminated
Hide Studies Not Open or Pending
Condition(s):Prader-Willi Syndrome; ObesityLast Updated:January 26, 2017Terminated
Condition(s):Prader-Willi SyndromeLast Updated:August 3, 2020Completed
Condition(s):Prader-Willi Syndrome; HyperphagiaLast Updated:April 18, 2023Completed
Condition(s):Prader-Willi SyndromeLast Updated:March 21, 2023Recruiting
Condition(s):Prader-Willi SyndromeLast Updated:March 6, 2024Recruiting
Condition(s):Prader-Willi SyndromeLast Updated:August 26, 2020Withdrawn
Condition(s):Prader-Willi SyndromeLast Updated:April 3, 2023Terminated
Condition(s):Prader-Willi Syndrome; Social BehaviorLast Updated:May 6, 2021Withdrawn
Condition(s):Prader-Willi Syndrome; ObesityLast Updated:June 19, 2012Completed
Condition(s):Hyperphagia; Prader-Willi SyndromeLast Updated:April 26, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.